374 related articles for article (PubMed ID: 35217640)
21. HERC3 promotes YAP/TAZ stability and tumorigenesis independently of its ubiquitin ligase activity.
Yuan B; Liu J; Shi A; Cao J; Yu Y; Zhu Y; Zhang C; Qiu Y; Luo H; Shi J; Cao X; Xu P; Shen L; Liang T; Zhao B; Feng XH
EMBO J; 2023 Feb; 42(4):e111549. PubMed ID: 36598329
[TBL] [Abstract][Full Text] [Related]
22. Hippo-YAP/TAZ signalling coordinates adipose plasticity and energy balance by uncoupling leptin expression from fat mass.
Choi S; Kang JG; Tran YTH; Jeong SH; Park KY; Shin H; Kim YH; Park M; Nahmgoong H; Seol T; Jeon H; Kim Y; Park S; Kim HJ; Kim MS; Li X; Bou Sleiman M; Lee E; Choi J; Eisenbarth D; Lee SH; Cho S; Moore DD; Auwerx J; Kim IY; Kim JB; Park JE; Lim DS; Suh JM
Nat Metab; 2024 May; 6(5):847-860. PubMed ID: 38811804
[TBL] [Abstract][Full Text] [Related]
23. Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a therapeutic target in YAP/TAZ-active cancers.
Gu Y; Wang Y; Sha Z; He C; Zhu Y; Li J; Yu A; Zhong Z; Wang X; Sun Y; Lan F; Yu FX
Cell Rep; 2022 Aug; 40(9):111296. PubMed ID: 36044856
[TBL] [Abstract][Full Text] [Related]
24. The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ.
Edwards DN; Ngwa VM; Wang S; Shiuan E; Brantley-Sieders DM; Kim LC; Reynolds AB; Chen J
Sci Signal; 2017 Dec; 10(508):. PubMed ID: 29208682
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of transcriptional coactivator YAP Impairs the expression and function of transcription factor WT1 in diabetic podocyte injury.
Chen J; Wang X; He Q; Yang HC; Fogo AB; Harris RC
Kidney Int; 2024 Jun; 105(6):1200-1211. PubMed ID: 38423183
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of YAP/TAZ pathway contributes to the cytotoxicity of silibinin in MCF-7 and MDA-MB-231 human breast cancer cells.
Fu J; Liu W; Liu S; Zhao R; Hayashi T; Zhao H; Xiang Y; Mizuno K; Hattori S; Fujisaki H; Ikejima T
Cell Signal; 2024 Jul; 119():111186. PubMed ID: 38643945
[TBL] [Abstract][Full Text] [Related]
27. TAZ/YAP fusion proteins: mechanistic insights and therapeutic opportunities.
Garcia K; Gingras AC; Harvey KF; Tanas MR
Trends Cancer; 2022 Dec; 8(12):1033-1045. PubMed ID: 36096997
[TBL] [Abstract][Full Text] [Related]
28. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility.
Wang Z; Wu Y; Wang H; Zhang Y; Mei L; Fang X; Zhang X; Zhang F; Chen H; Liu Y; Jiang Y; Sun S; Zheng Y; Li N; Huang L
Proc Natl Acad Sci U S A; 2014 Jan; 111(1):E89-98. PubMed ID: 24367099
[TBL] [Abstract][Full Text] [Related]
29. TAZ Protein Accumulation Is Negatively Regulated by YAP Abundance in Mammalian Cells.
Finch-Edmondson ML; Strauss RP; Passman AM; Sudol M; Yeoh GC; Callus BA
J Biol Chem; 2015 Nov; 290(46):27928-38. PubMed ID: 26432639
[TBL] [Abstract][Full Text] [Related]
30. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
Jang JW; Kim MK; Bae SC
Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
[TBL] [Abstract][Full Text] [Related]
31. Role of the Hippo pathway and mechanisms for controlling cellular localization of YAP/TAZ.
Kwon H; Kim J; Jho EH
FEBS J; 2022 Oct; 289(19):5798-5818. PubMed ID: 34173335
[TBL] [Abstract][Full Text] [Related]
32. A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
Hillen H; Candi A; Vanderhoydonck B; Kowalczyk W; Sansores-Garcia L; Kesikiadou EC; Van Huffel L; Spiessens L; Nijs M; Soons E; Haeck W; Klaassen H; Smets W; Spieser SA; Marchand A; Chaltin P; Ciesielski F; Debaene F; Chen L; Kamal A; Gwaltney SL; Versele M; Halder GA
Mol Cancer Ther; 2024 Jan; 23(1):3-13. PubMed ID: 37748190
[TBL] [Abstract][Full Text] [Related]
33. YAP and TAZ regulate skin wound healing.
Lee MJ; Byun MR; Furutani-Seiki M; Hong JH; Jung HS
J Invest Dermatol; 2014 Feb; 134(2):518-525. PubMed ID: 24108406
[TBL] [Abstract][Full Text] [Related]
34. A Non-canonical Role of YAP/TEAD Is Required for Activation of Estrogen-Regulated Enhancers in Breast Cancer.
Zhu C; Li L; Zhang Z; Bi M; Wang H; Su W; Hernandez K; Liu P; Chen J; Chen M; Huang TH; Chen L; Liu Z
Mol Cell; 2019 Aug; 75(4):791-806.e8. PubMed ID: 31303470
[TBL] [Abstract][Full Text] [Related]
35. The Hippo Pathway Prevents YAP/TAZ-Driven Hypertranscription and Controls Neural Progenitor Number.
Lavado A; Park JY; Paré J; Finkelstein D; Pan H; Xu B; Fan Y; Kumar RP; Neale G; Kwak YD; McKinnon PJ; Johnson RL; Cao X
Dev Cell; 2018 Dec; 47(5):576-591.e8. PubMed ID: 30523785
[TBL] [Abstract][Full Text] [Related]
36. The novel YAP target gene, SGK1, upregulates TAZ activity by blocking GSK3β-mediated TAZ destabilization.
Yoo G; Kim T; Chung C; Hwang DS; Lim DS
Biochem Biophys Res Commun; 2017 Aug; 490(3):650-656. PubMed ID: 28634071
[TBL] [Abstract][Full Text] [Related]
37. The Hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1.
Hansen CG; Ng YL; Lam WL; Plouffe SW; Guan KL
Cell Res; 2015 Dec; 25(12):1299-313. PubMed ID: 26611634
[TBL] [Abstract][Full Text] [Related]
38. EP300 promotes lung cancer cell proliferation by regulating the oncogenic transcription of Hippo-YAP signaling pathway.
Li S; Shi J; Wang L; Zhang D; Zhang H
Biochem Biophys Res Commun; 2024 Jan; 692():149330. PubMed ID: 38048728
[TBL] [Abstract][Full Text] [Related]
39. Targeting YAP and Hippo signaling pathway in liver cancer.
Liu AM; Xu MZ; Chen J; Poon RT; Luk JM
Expert Opin Ther Targets; 2010 Aug; 14(8):855-68. PubMed ID: 20545481
[TBL] [Abstract][Full Text] [Related]
40. YAP-Hippo signalling downstream of leukemia inhibitory factor receptor: implications for breast cancer.
Hergovich A
Breast Cancer Res; 2012 Dec; 14(6):326. PubMed ID: 23216692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]